MK-677 (Ibutamoren) MMA / Combat Sports Protocol

What MK-677 Actually Does in the Body

MK-677 mimics ghrelin at the growth hormone secretagogue receptor (GHSR-1a), triggering pulsatile GH release from the pituitary without suppressing the hypothalamic-pituitary axis. The resulting IGF-1 elevation drives anabolic and repair signaling across muscle, bone, and connective tissue.

Mechanism at the receptor level

MK-677 binds GHSR-1a with high affinity and oral bioavailability. Unlike exogenous recombinant GH, it preserves the natural pulsatile pattern of GH secretion, which matters because sustained supraphysiologic GH flatlines receptor sensitivity. A 1998 dose-escalation study by Chapman et al. (N=32 healthy older adults) published in the Journal of Clinical Endocrinology and Metabolism confirmed that oral MK-677 at 25 mg/day raised mean 24-hour GH secretion by 97% and IGF-1 by 52% above baseline within two weeks [1].

Why pulsatility matters for fighters

Pulsatile GH secretion aligns with slow-wave (N3) sleep, the phase during which most musculoskeletal repair occurs. A randomized crossover trial by Svensson et al. Demonstrated that MK-677 at 25 mg significantly increased REM latency reduction and slow-wave sleep duration in young adults [2]. For a fighter who trains twice daily and absorbs repeated sub-concussive and concussive forces, extending N3 sleep is not a minor detail. It is where collagen cross-linking, satellite cell activation, and glymphatic clearance of neurotoxic waste products overlap in a single restorative window.

IGF-1 as the downstream effector

Elevated IGF-1 promotes type I and III collagen synthesis in tendons and ligaments, accelerates myofibril repair, and stimulates osteoblast activity. A 24-month RCT by Nass et al. (N=65) showed that MK-677 25 mg/day maintained IGF-1 in the upper-normal range and increased lean body mass by 1.6 kg vs. Placebo over two years in GH-deficient adults [3].

The MMA-Specific Rationale: Impact, Concussion, and Soft Tissue

Combat sports generate a distinct injury profile. Repetitive sub-concussive blows, acute ligament sprains, cartilage compression, and rib stress fractures create compounding tissue debt that standard recovery windows often cannot clear. MK-677 addresses several of these pathways simultaneously.

Brain protection and glymphatic clearance

Repeated head trauma elevates serum neurofilament light chain (NfL) and GFAP, biomarkers of axonal and astrocytic injury. IGF-1 crosses the blood-brain barrier and exerts neuroprotective effects by activating PI3K/Akt survival signaling and reducing neuroinflammatory cytokine expression. A systematic review by Torres-Aleman and colleagues in Neuroscience identified IGF-1 as a key mediator of neuronal resistance to oxidative stress [4]. The glymphatic system, which clears amyloid-beta and tau during N3 sleep, is directly amplified by the sleep-architecture changes MK-677 produces. Fighters absorbing daily sparring contact may benefit from this dual mechanism more than any other athlete population.

Soft-tissue and tendon repair

Tendons are notoriously hypovascular. Healing after partial tears or chronic tendinopathy depends on fibroblast proliferation and collagen deposition, both upregulated by IGF-1. A 2007 study by Doessing et al. Published in the Journal of Physiology showed that GH administration increased collagen synthesis rate in patellar and Achilles tendons by approximately 36% over 3 to 4 weeks in healthy men, with IGF-1 acting as the primary local mediator [5]. MK-677's ability to sustain elevated IGF-1 for months positions it as a rational adjunct during the rehabilitation phase after ligamentous injury or chronic tendinopathy common in grapplers and strikers.

Bone density and fracture resilience

Metacarpal, rib, and orbital stress fractures occur at high rates in competitive fighters. MK-677 stimulates osteoblast-mediated bone formation. A 12-month RCT by Murphy et al. In healthy older adults found that MK-677 25 mg/day increased bone mineral density at the femoral neck by 1.3% vs. A decrease of 0.22% in placebo, alongside significant increases in osteocalcin and bone-specific alkaline phosphatase [6].

Structured Protocol for Combat Athletes

This protocol reflects evidence-informed practitioner consensus adapted for the MMA athlete context. No RCT has been conducted exclusively in combat-sport competitors. Evidence levels are labeled throughout.

Phase 1: Onboarding (weeks 1 to 4)

Dose: 12.5 mg orally at bedtime. Rationale: Starting at half the standard dose allows the athlete to calibrate appetite stimulation and water retention without disrupting weight-class management during active camp. IGF-1 should rise measurably within 14 to 21 days even at this dose [1].

Labs at baseline (before day 1):

• IGF-1 (ng/mL)
• Fasting glucose and HbA1c
• Fasting insulin
• LH, FSH, total testosterone (to rule out pre-existing axis suppression)
• Prolactin
• CMP (comprehensive metabolic panel)
• Lipid panel

Monitoring note: MK-677 can transiently raise fasting glucose through GH-mediated insulin resistance, particularly at 25 mg. Fighters with a baseline fasting glucose above 100 mg/dL or any personal history of glucose intolerance should start at 12.5 mg and recheck fasting glucose at week 4 before escalating.

Phase 2: Full dose (weeks 5 to 24)

Dose: 25 mg orally at bedtime.

Escalating to 25 mg at week 5 optimizes IGF-1 elevation for the tissue-repair and sleep phases of a standard 8 to 12-week training camp. The bedtime timing is non-negotiable: GH secretion peaks in the first 90 minutes of sleep, and MK-677 taken in the morning blunts this natural pulse while adding diurnal fatigue and increased appetite during hours when caloric discipline is required.

Expected outcomes by week 8 to 12 (evidence level: RCT extrapolation):

• IGF-1 increase of 40 to 60% above baseline [1,3]
• Subjective sleep quality improvement reported within 2 to 3 weeks [2]
• Lean mass gain of 1 to 2 kg over 12 weeks (partially water weight initially) [3]
• Reduced morning joint stiffness reported in observational practitioner data

Weight-class management: The initial 2 to 4 kg of water retention typically stabilizes by week 6. Fighters who cut weight should plan MK-677 use in the off-season or early camp, not the final 3 to 4 weeks before a weigh-in.

Phase 3: Maintenance or cycling (weeks 25 to 52)

Some practitioners extend MK-677 continuously for up to 52 weeks based on the Nass et al. 24-month safety data [3]. Others prefer a 12-week-on / 4-week-off structure to allow any GH axis feedback to normalize. The off-cycle period also provides a useful assessment window: if sleep quality and recovery metrics deteriorate during the break, the athlete has a clear functional signal that the compound was contributing meaningfully.

Off-season vs. In-camp prioritization:

| Period | Dose | Primary Goal | |---|---|---| | Off-season (tissue remodeling) | 25 mg nightly | Collagen synthesis, bone density, lean mass | | Early camp (weeks 1 to 8 of 12) | 25 mg nightly | Sleep recovery, connective tissue support | | Late camp (final 3 to 4 weeks) | Taper to 12.5 mg or discontinue | Reduce water retention before weigh-in | | Post-fight recovery | 25 mg nightly for 4 to 6 weeks | Accelerate repair of acute trauma |

Lab Monitoring Protocol

Monitoring is not optional with MK-677. GH secretagogues shift glucose metabolism in a dose-dependent manner, and IGF-1 levels above the upper reference range for age have been associated with increased cancer risk in epidemiological data, though causality remains unestablished [7].

Monitoring schedule

Baseline: Full panel as listed in Phase 1.

Week 4: Fasting glucose, fasting insulin, IGF-1.

Week 12: Full panel repeat. If IGF-1 exceeds 350 ng/mL in an athlete under 35, reduce dose to 12.5 mg. If fasting glucose exceeds 110 mg/dL, add HbA1c and consider dose reduction or discontinuation.

Week 24: Full panel. Bone turnover markers (osteocalcin, bone-specific ALP) optional but useful for tracking skeletal adaptation.

IGF-1 target range

The clinical target for MK-677 use in adult athletes is an IGF-1 between 200 to 350 ng/mL, corresponding approximately to the 50th, 90th percentile for a healthy 25 to 35-year-old male per the Endocrine Society reference ranges [8]. Values above 400 ng/mL warrant dose reduction regardless of symptom profile.

Glucose management

If fasting glucose rises above 100 mg/dL on 25 mg/day, shifting the dose to immediately after the last meal of the day (rather than at bedtime in a fasted state) reduces the insulin-antagonizing window. Berberine 500 mg twice daily has been used empirically by practitioners to blunt MK-677-associated glucose elevation, though no RCT has tested this combination specifically.

Side Effects and Risk Management

MK-677 is generally well-tolerated in clinical trial populations. The Chapman et al. Data showed no serious adverse events at 25 mg/day over 2 years in older adults [1]. The relevant side-effect profile for fighters includes:

Appetite increase: Consistent and significant. Useful during bulk phases; problematic during a weight cut. Plan accordingly.

Water retention: Primarily in weeks 1 to 4. Usually 2 to 4 lbs of extracellular fluid. Resolves partially with time.

Fatigue if dosed in daytime: Taking MK-677 in the morning produces sedation during training hours. Always dose at night.

Transient fasting hyperglycemia: Most pronounced in athletes with baseline insulin resistance. Monitor fasting glucose at week 4.

Mild prolactin elevation: Reported in some users. A prolactin check at week 12 identifies outliers. Values above 25 ng/mL in men warrant dose reduction.

Carpal tunnel syndrome: GH-mediated fluid retention can compress the median nerve. Rare at 25 mg but documented in the GH replacement literature [9].

Expected Timeline of Outcomes

Recovery improvements are not immediate. Fighters should calibrate expectations to the biological timelines of the tissues being repaired.

Weeks 1 to 2

Sleep quality may improve within 7 to 14 days. This is the fastest-responding outcome and serves as the earliest functional signal that MK-677 is working. If sleep quality does not improve by week 3, confirm pill identity and check IGF-1.

Weeks 3 to 6

IGF-1 peaks in this window at 25 mg/day. Appetite increases noticeably. Water retention is highest in this phase. Joint inflammation and morning stiffness typically begin to ease by week 6 in athletes with chronic tendinopathy.

Weeks 8 to 16

Connective tissue adaptations become measurable. Tendon stiffness (a marker of healthy collagen cross-linking) increases by week 12 to 16 per the Doessing data extrapolation [5]. Athletes with rib stress fractures or metacarpal fractures may note faster radiographic callus formation, consistent with the bone turnover data from Murphy et al. [6].

Weeks 17 to 24

Lean mass gains become distinguishable from water weight. Body composition scans (DEXA) at 24 weeks typically show 1 to 2 kg of lean mass gain with stable or reduced fat mass, consistent with the Nass et al. 24-month trajectory [3].

Drug Interactions and Contraindications

Contraindications:

• Active malignancy or personal history of hormone-sensitive cancer
• Uncontrolled type 2 diabetes or fasting glucose above 126 mg/dL
• Active acromegaly or pituitary tumor
• Pregnancy

Interactions to note:

• Insulin and insulin secretagogues: MK-677's glucose-elevating effect may require dose adjustment in athletes using metformin or insulin.
• Corticosteroids: Reduce GH secretion and blunt MK-677 response.
• Cyclosporine: Case reports suggest increased exposure; avoid combination.

Regulatory and Anti-Doping Considerations

MK-677 is not FDA-approved for any indication. It was investigated under IND protocols by Merck and later by Lilly but never received NDA approval. Current FDA guidance classifies unapproved GH secretagogues as investigational drugs not legal for sale as dietary supplements [10].

WADA's 2024 Prohibited List does not name MK-677 by compound, but Section S2 prohibits peptide hormones, growth factors, related substances, and mimetics. The GHSR-1a agonist mechanism of MK-677 places it in a gray zone. Athletes competing under WADA jurisdiction should obtain a formal ruling from their sport's governing body before use. UFC athletes operating under USADA's WADA-aligned program should treat MK-677 as presumptively prohibited until a formal TUE review confirms otherwise.

Practitioner Perspective on Combat-Sport Use

The rationale for MK-677 in MMA is mechanistically sound: the compound addresses the sleep deficit, the connective tissue degradation, and the neuroinflammatory load that define professional fighting. What separates this from speculative peptide use is that each of those three targets has a corresponding clinical dataset, even if none of those datasets enrolled fighters specifically. The Chapman RCT established the IGF-1 dose-response. The Svensson crossover established the sleep architecture effect. The Doessing trial established the collagen synthesis effect. A physician using MK-677 in a combat athlete is connecting three evidence threads, not relying on anecdote.

The weakest link remains glucose metabolism. Fighters who are already insulin-resistant from years of extreme weight cuts are the highest-risk subgroup. For those athletes, 12.5 mg at night after the last meal, with a week-4 fasting glucose check, is the appropriate starting point.